Rimonabant Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Rimonabant evidence and protocol review

Metabolic Research compound TabletPowder verified

Also known as: SR141716, Acomplia

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

20 mg historical Acomplia tablet, 1 g RUO powder, 5 g RUO powder

Storage

No approved consumer storage standard exists for this presentation; follow the lot-specific COA and validated stability data

Solubility

Form, salt, and formulation dependent; verify the lot-specific COA

Catalog Description

Rimonabant was the first selective CB1 cannabinoid receptor antagonist/inverse agonist introduced into clinical practice for obesity and cardiometabolic disorders, and was effective in mitigating obesity and its complications in trials. However, it was withdrawn from the market (it was never FDA-approved in the US, and was withdrawn in Europe) due to markedly increased rates of CNS-mediated neuropsychiatric side effects - depressed mood, anxiety, irritability, insomnia, and suicidality - which halted further therapeutic development of the entire first-generation CB1-antagonist drug class. This history has directly motivated research into 'second-generation,' peripherally restricted CB1 antagonists (with limited brain penetrance) that aim to replicate rimonabant's metabolic benefits in rodent obesity/diabetes models without the CNS side effects.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

~6-9 days (long half-life; contributed to prolonged psychiatric adverse-event exposure)

Onset

Metabolic benefits and psychiatric adverse events both reported over weeks to months in trials

Administration Routes (Research)

Oral

Reported Research Effects

CB1 receptor antagonism/inverse agonism - effective for obesity/cardiometabolic outcomes in trials
Markedly increased rates of depression, anxiety, and suicidality (led to worldwide withdrawal)

Reported Research Side Effects

Depressed mood
Anxiety
Irritability
Insomnia
Suicidal ideation and behavior
Psychiatric adverse events were approximately doubled and led to market suspension

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

20 mg once daily was the authorized European Acomplia regimen before suspension and withdrawal [Oral; Historical withdrawn product; Daily]Source: EMA Acomplia record; not a current protocol

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Current major depression
Suicidal ideation or history requiring specialist assessment
Antidepressant therapy without specialist review
Any use outside an approved research protocol

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

Rimonabant was authorized in Europe at 20 mg daily, suspended in 2008, and withdrawn in 2009 after the benefit-risk balance became unfavorable because of psychiatric harm. This historical regimen is retained for database completeness and is not a present-use recommendation.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Acomplia European public assessment record — European Medicines Agency
https://www.ema.europa.eu/en/medicines/human/EPAR/acomplia

EMA recommendation to suspend Acomplia — European Medicines Agency
https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-suspension-marketing-authorisation-acomplia

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.